COPD symptoms in the morning: Impact, evaluation and management

Respiratory Research

Volumn 14, Issue 1, 2013, Pages

  Roche, Nicolas ^a   Chavannes, Niels H ^b   Miravitlles, Marc ^c  

^a Institut Cochin   (France)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Long acting muscarinic antagonists; Long acting 2 agonists; Morning symptoms; Once daily; Onset of action

Indexed keywords

ACLIDINIUM BROMIDE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; PLACEBO; QVA 149; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ADD ON THERAPY; BRONCHODILATATION; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIRCADIAN RHYTHM; CLINICAL EVALUATION; CLINICAL FEATURE; COUGHING; DISEASE CONTROL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MONOTHERAPY; MORNING DOSAGE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; REVIEW; SLEEP DISORDER; SPUTUM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYMPTOM; TREATMENT RESPONSE; WHEEZING; ABSENTEEISM; DAILY LIFE ACTIVITY; DRUG THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RISK FACTOR; SICKNESS IMPACT PROFILE;

ABSENTEEISM; ACTIVITIES OF DAILY LIVING; CIRCADIAN RHYTHM; DRUG THERAPY; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; SICKNESS IMPACT PROFILE;

EID: 84885794314     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-14-112     Document Type: Review

References (48)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management and prevention of COPD 2013, Update. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html, Global Initiative for Chronic Obstructive Lung Disease (GOLD).
2. Fletcher MJ, Upton J, Taylor-Fishwick J, Buist SA, Jenkins C, Hutton J, Barnes N, Van Der Molen T, Walsh JW, Jones P, Walker S. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health 2011, 11:612. 10.1186/1471-2458-11-612, 3163200, 21806798.
3. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009, 25:2043-2048. 10.1185/03007990903103006, 19569976.
4. O'Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD 2006, 3:219-232. 10.1080/15412550600977478, 17361503.
5. Laveneziana P, Parker CM, O'Donnell DE. Ventilatory constraints and dyspnea during exercise in chronic obstructive pulmonary disease. Appl Physiol Nutr Metab 2007, 32:1225-1238. 10.1139/H07-119, 18059601.
6. Higgins V, Broomfield S, Pollard R, Fermer S. Impact of morning symptoms on the working lives of COPD patients 2012, Birmingham, UK: International Conference for Chronic Obstructive Pulmonary Disease, Abstract.
7. Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011, 37:264-272. 10.1183/09031936.00051110, 21115606.
8. Small M, Broomfield M, Pollard R, Fermer S. Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler use and normal daily activities. Eur Resp J 2012, 40(56):3476. Abstract.
9. Kessler R, Stahl E, Vogelmeier C, Haughney J, Trudeau E, Lofdahl CG, Partridge MR. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006, 130:133-142. 10.1378/chest.130.1.133, 16840393.
10. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129:509-517. 10.1378/chest.129.3.509, 16537846.
11. Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003, 58:855-860. 10.1136/thorax.58.10.855, 1746483, 14514937.
12. McCarley C, Hanneman SK, Padhye N, Smolensky MH. A pilot home study of temporal variations of symptoms in chronic obstructive lung disease. Biol Res Nurs 2007, 9:8-20. 10.1177/1099800407303501, 17633443.
13. Kuyucu T, Guclu SZ, Saylan B, Demir C, Senol T, Guner S, Koyuncu E, Ozen F, Ozturk S, Cangul Z, Aganoglu S, Ozkaya S, Ocak SC, Akkurt H, Intepe YS, Bayrak MG, Guler T, Bekci TT, Soyyigit S, Seyfettin S, Kula O, Akbay MO, Buyukgoze B, Asal G, Baslilar S, Ozturk O. A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study. Tuberk Toraks 2011, 59:328-339. 10.5578/tt.3268, 22233302.
14. Kim YJ, Lee BK, Jung CY, Jeon YJ, Hyun DS, Kim KC, Yu SK, Choi HS, Shin WH, Lee KH. Patient's perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL study. Korean J Intern Med 2012, 27:426-435. 10.3904/kjim.2012.27.4.426, 3529242, 23269884.
15. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138. 10.1056/NEJMoa0909883, 20843247.
16. Miravitlles M, Llor C, de Castellar R, Izquierdo I, Baro E, Donado E. Validation of the COPD severity score for use in primary care: the NEREA study. Eur Respir J 2009, 33:519-527. 10.1183/09031936.00087208, 19164354.
17. Partridge MR, Miravitlles M, Stahl E, Karlsson N, Svensson K, Welte T. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J 2010, 36:96-104. 10.1183/09031936.00123709, 19897551.
18. Food US, Administration D. Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Fed Regist 2009, 74:65132-65133.
19. Palsgrove A, Houghton K, Hareendran A, Scaefer M, Setyawan J, Mocarski M. The development of the early morning symptoms of COPD instrument (EMSCI). Value Health 2011, 14(7):A496-A497. Abstract PRS51.
20. Kinsman RA, Yaroush RA, Fernandez E, Dirks JF, Schocket M, Fukuhara J. Symptoms and experiences in chronic bronchitis and emphysema. Chest 1983, 83:755-761. 10.1378/chest.83.5.755, 6839816.
21. Reishtein JL. Relationship between symptoms and functional performance in COPD. Res Nurs Health 2005, 28:39-47. 10.1002/nur.20054, 15625710.
22. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia GE, Caracta CF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012, 9:90-101. 10.3109/15412555.2012.661492, 22320148.
23. Miravitlles M, Iriberri M, Barrueco M, Lleonart M, Villarrubia E, Galera J. Usefulness of the LCOPD, CAFS and CASIS Scales in understanding the impact of COPD on Patients. Respiration 2012, [Epub ahead of print]: doi:10.1159/000341175.
24. Beier J, Kirsten AM, Mruz R, Segarra R, Chuecos F, Caracta C, Gil EG. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD 2013, 10:511-522. 10.3109/15412555.2013.814626, 3787813, 23819698.
25. Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falques M, Caracta CF, Garcia GE. Efficacy of aclidinium bromide 400 mug twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012, 141:745-752. 10.1378/chest.11-0406, 21903737.
26. Welte T, Metzenauer P, Hartmann U. Once versus twice daily formoterol via Novolizer for patients with moderate to severe COPD-a double-blind, randomised, controlled trial. Pulm Pharmacol Ther 2008, 21:4-13. 10.1016/j.pupt.2006.09.002, 17101285.
27. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19:217-224. 10.1183/09031936.02.00269802, 11866001.
28. Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010, 23:257-267. 10.1016/j.pupt.2010.03.003, 20381630.
29. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010, 65:473-479. 10.1136/thx.2009.125435, 20522841.
30. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010, 182:155-162. 10.1164/rccm.200910-1500OC, 20463178.
31. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011, 37:273-279. 10.1183/09031936.00045810, 20693243.
32. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:778-784. 10.1164/ajrccm.164.5.2007006, 11549532.
33. Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009, 3:1-11.
34. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia GE. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012, 40:830-836. 10.1183/09031936.00225511, 22441743.
35. Kerwin E, Rennard S, Gelb S. Twice-daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in Accord COPD I. Am J Respir Crit Care Med 2011, 183:A1592.
36. Maltais F, Celli B, Casaburi R, Porszasz J, Jarreta D, Seoane B, Caracta C. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2011, 105:580-587. 10.1016/j.rmed.2010.11.019, 21183326.
37. Singh D, Bateman ED, Jones PW. Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD). Eur Resp J 2011, 38(Suppl. 55):875.
38. Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD 2010, 7:331-336. 10.3109/15412555.2010.510158, 20854047.
39. Agusti J, Jones PW, Bateman E. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN. Eur Resp J 2011, 38(Suppl. 55):874.
40. D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011, 12:156. 10.1186/1465-9921-12-156, 3266210, 22151296.
41. Fogarty C, Hattersley H, Di Scala L, Drollmann A. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2011, 105:337-342. 10.1016/j.rmed.2010.10.021, 21144724.
42. Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VK, Lu Y, Banerji D. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012, 40:1106-1114. 10.1183/09031936.00040712, 3485572, 23060624.
43. Verkindre C, Fukuchi Y, Flemale A, Takeda A, Overend T, Prasad N, Dolker M. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010, 104:1482-1489. 10.1016/j.rmed.2010.04.006, 20541381.
44. Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Guclu SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 2010, 23:438-444. 10.1016/j.pupt.2010.04.005, 20416390.
45. Beeh K, Singh D, Di Scala L. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012, 7:513-515.
46. Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, Banerji D. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013,
47. NCT01712516 A 12-week treatment, multi-center, randomized, double-blind, parallel-group, placebo and active controlled study to assess the efficacy, safety, and tolerability of indacaterol maleate / glycopyrronium bromide in COPD patients with moderate to severe airflow limitation 2013, http://clinicaltrials.gov/ct2/results?term=NCT+01712516; Last accessed 18, NCT01712516.
48. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:741-750. 10.1164/rccm.200904-0492OC, 19644045.